> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Additional Benlysta Indication Approved
- URL: https://www.fdaweb.com/additional-benlysta-indication-approved/
- Published: 2022-07-27T12:00:00.000Z
- Updated: 2026-09-14T17:53:32.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152386

FDA has approved an additional indication for GlaxoSmithKline’s Benlysta (belimumab) to treat children age 5 to 17 with active lupus nephritis who are receiving standard therapy. The company [says](https://www.businesswire.com/news/home/20220727005841/en/GSK-Announces-US-FDA-Approval-of-Benlysta-Belimumab-for-Pediatric-Patients-With-Active-Lupus-Nephritis?ref=fdaweb.com) the approval extends the current U.S. indication to include both lupus and active lupus nephritis for the intravenous formulation in the pediatric patient population. It is the first FDA-approved treatment for pediatric lupus nephritis, GSK says.